Clinical Trial Update: Visugromab, Nivolumab and a Tyrosine Kinase Inhibitor (TKI) Compared to Double Placebo and a TKI in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Visugromab, Nivolumab, and a Tyrosine Kinase Inhibitor versus double placebo and a TKI in unresectable or metastatic hepatoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tyrosine kinase inhibitor (unspecified)
• Visugromab (Visugromab)
• nivolumab (nivolumab)

Snippet

Sponsor: CatalYm GmbH | Conditions: Unresectable or Metastatic Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Anti PD-(L)1 Compound | Phase 2 | Status: NOT_YET_RECRUITING